Russian Pharma Sector Analysis

Russian Pharma Sector Analysis

According to “Russian Pharma Sector Analysis”, the Russian pharmaceutical market grew at a slow pace in 2007 but it still is attractive as compared to previous years that recorded no-so-impressive performance due to the state segment. In the Russian pharma market, both the retail segment and parapharmaceutical market registered double-digit growth in sales value, with parapharmaceutical recording the highest growth rate and retail segment contributing the maximum share in sales value terms.

This research report provides an extensive research and objective analysis on the growing demand of pharmaceuticals in Russia and presents a clear picture of the country’s healthcare and pharmaceutical market. It covers Russian demographics, structure of healthcare sector, size and growth of pharmaceutical market, leading drugs, segment-wise break up, and information on major therapy areas to give strategic insight into the market. This report briefly discusses the major players operating in each segment of the market. The share of imported and domestic drugs, RX and OTC drugs, and sales structure by ATC group has also been analyzed in context of the Russian pharmaceutical market.

Key Research Findings

• The Russian pharmaceutical market grew 16% in 2007 as compared to 2006.
  
  
• State segment grew at a slower rate while the parapharmaceutical and commercial segments recorded impressive growth rates in 2007.
  
  
• In 2007, new drugs segment increased at fast pace as more than 230 new drug trade names appeared in the Russian pharmaceutical market.
  
  
• In 2007, Sanofi-Aventis was the leader of the retail sales among the drug manufacturers in commercial drug market segment.
  
  
• The consumption value provided by the State Reimbursement Program (DLO) decreased in 2007 due to diminishing requirement.
  
  
• The Russian pharmaceutical market is forecasted to grow at a CAGR of 14.36% by 2012.

Key Issues Analyzed in the Report

• Where does the Russian pharmaceutical market stand in comparison to other key global markets?
  
  
• What is the market size of various segments in the Russian pharmaceutical industry?
  
  
• What is the proportion of domestic and imported drugs in each segment?
  
  
• What are the opportunities that will emerge in future for the market?
  
  
• Who are the major players in the Russian pharmaceutical market?

Research Methodology Used in the Report

Information Sources
The information in this report has been taken from various credible sources like books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods
The analysis methods used in this report include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

For the purpose of this report, the Russian pharmaceutical market has been considered to consist of the following segments:

• Commercial drugs market;
  
  
• State segment (DLO programme and Hospital Segment)
  
  
• Parapharmaceutical segment (Food Supplements and Cosmetics)

 
 

1. Analyst View

2. Global Pharmaceutical Market

2.1 Geographical Performance

2.2 Leading Therapy Classes

2.3 Leading Companies

2.4 Leading Drugs

3. Russia - Demographics & Healthcare Profile

3.1 Life Expectancy

3.2 Age Breakup

3.3 Hospital Beds & Doctors

3.4 Healthcare Expenditure

4. Pharmaceutical Market

4.1 Market Size & Growth

4.2 Comparative Analysis

4.3 Commercial Drugs Market

4.3.1 Trends

4.3.2 Imported & Domestic Drugs

4.3.3 RX & OTC Drugs

4.3.4 Sales Structure - By ATC Groups

4.3.5 Leading Companies

4.3.6 Leading Drugs

4.3.7 Price Analysis

4.4 State Segment

4.4.1 DLO Reimbursement Programme

4.4.1.1 Imported & Domestic Drugs

4.4.1.2 RX & OTC Drugs

4.4.1.3 Sales Structure - By ATC Groups

4.4.1.4 Leading Companies

4.4.1.5 Leading Drugs

4.4.2 Hospital Segment

4.4.2.1 Imported & Domestic Drugs

4.4.2.2 Leading Companies

4.4.2.3 Leading Drugs

4.4.2.4 Drugs Demand - By Price

4.5 Parapharmaceutical Market

4.5.1 Nutritional Supplements Market

4.5.1.1 Imported & Domestic Supplements

4.5.1.2 Leading Supplements

4.5.1.3 Supplement Demand - By Price

4.6 New Drugs

5. Industry Analysis

5.1 Market Driving Forces

5.1.1 Aging Population

5.1.2 Increasing Volume & Sales of Expensive Drugs

5.1.3 Government Support & Funding

5.1.4 Medical Insurance

5.1.5 Growing Disposable Income

5.2 Growth Avenues

5.2.1 Cardiovascular Drugs

5.2.2 HIV Drugs

5.2.3 High Insulin Demand

5.2.4 Cancer Drugs

5.2.5 Foreign Players

5.2.6 Generics

5.2.7 Clinical Trials Market

5.3 Market Roadblocks

5.3.1 Declining Population

5.3.2 Low Growth in Spending under DLO Programme

5.3.3 Price Control

5.3.4 Drug Counterfeiting & Weak IPR Regime

6. Future Outlook (2008-2012)

6.1 Commercial Drugs Market

6.2 State Segment

6.3 Parapharmaceutical Market

7. Key Players

7.1 Sanofi-Aventis

7.2 Novartis International AG

7.3 Roche Group

7.4 Pfizer Inc

7.5 AstraZeneca Plc

List of Figures:

Figure 2-1: Global - Pharmaceutical Market (in Billion US$), 2002-2007

Figure 2-2: Global - Growth of Pharmaceutical Market (%), 2002-2007

Figure 2-3: Global - Pharmaceutical Market* by Region (%), 2007

Figure 2-4: Global - Top Five Pharmaceutical Companies by Sales & Net Income (in Billion US$), 2007

Figure 3-1: Russia - Population (in Million), 2002-2007

Figure 3-2: Russia - Life Expectancy of Male & Female (in Years), 2002-2008E

Figure 3-3: Russia - Population Breakup by Age (%), 2002-2008E

Figure 3-4: Russia - Number of Doctors (per ‘000 Population), 2002-2007E

Figure 3-5: Russia - Number of Hospital Beds (per ‘000 Population), 2002-2007E

Figure 3-6: Russia - Share of Healthcare Expenditure in GDP (%), 2002-2007E

Figure 3-7: Russia - Per Capita Healthcare Expenditure (in US$), 2002-2007E

Figure 4-1: Russia - Pharmaceutical Market (in Million US$), 2006 & 2007

Figure 4-2: Russia - Share of Key Segments in Pharmaceutical Market (%), 2006 & 2007

Figure 4-3: Global - Top Pharmaceutical Retail Markets (in Billion US$), 2007

Figure 4-4: Global - Growth of Top Pharmaceutical Retail Markets (%), 2007

Figure 4-5: Global - Per Capita Drug Consumption in Top Pharmaceutical Markets (in US$), 2006

Figure 4-6: Russia - Share of Personal & State Financing in Pharmaceutical Market (%), 2004-2006

Figure 4-7: Global - Share of Personal & State Financing in Top Pharmaceutical Markets (%), 2006

Figure 4-8: Russia - Commercial Drugs Market (in Million US$), 2006 & 2007

Figure 4-9: Russia - Trends in Commercial Drugs Market (%), 2007

Figure 4-10: Russia - Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (%), 2006 & 2007

Figure 4-11: Russia - Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Volume (%), 2006 & 2007

Figure 4-12: Russia - Share of RX & OTC Drugs in Commercial Drugs Market by Sales Value (%), 2006 & 2007

Figure 4-13: Russia - Share of RX & OTC Drugs in Commercial Drugs Market by Sales Volume (%), 2006 & 2007

Figure 4-14: Russia - Growth* of Major ATC Groups in Commercial Drugs Market (%), 2007

Figure 4-15: Russia - Price Index for Drugs in Commercial Drugs Market (%), 2005-2007

Figure 4-16: Russia - Price Index for Imported & Domestic Drugs in Commercial Drugs Market (%), 2005-2007

Figure 4-17: Russia - Consumer Price Index (%), 2007

Figure 4-18: Russia - State Segment of Pharmaceutical Market (in Million US$), 2006 & 2007

Figure 4-19: Russia - Consumption under DLO Programme (in Billion US$), 2006* & 2007

Figure 4-20: Russia - Share of Imported & Domestic Drugs in the DLO List of Full & Trade Name (%), 2007

Figure 4-21: Russia - Share of Imported & Domestic Drugs under DLO Programme by Sales Value (%), 2006 & 2007

Figure 4-22: Russia - Share of RX & OTC Drugs under DLO Programme by Sales Value (%), 2006 & 2007

Figure 4-23: Russia - Share of RX & OTC Drugs under DLO Programme by Sales Volume (%), 2006 & 2007

Figure 4-24: Russia - Share of ATC Groups under DLO Programme by Sales Value (%), 2006 & 2007

Figure 4-25: Russia - Share of Imported & Domestic Drugs under Hospital Segment by Sales Value (%), 2006 & 2007

Figure 4-26: Russia - Share of Imported & Domestic Drugs under Hospital Segment by Sales Volume (%), 2006 & 2007

Figure 4-27: Russia - Drugs Demand by Price under Hospital Segment (%), 2007

Figure 4-28: Russia - Parapharmaceutical Market (in Million US$), 2006 & 2007

Figure 4-29: Russia - Nutritional Supplements Market (in Million US$), 2005 & 2006

Figure 4-30: Russia - Nutritional Supplements Market (in Million Units), 2005 & 2006

Figure 4-31: Russia - Share of Imported & Domestic Nutritional Supplements Sales* (%), 2006

Figure 4-32: Russia - Breakup* of Imported Nutritional Supplements by Country (%), 2006

Figure 4-33: Russia - Imported & Domestic Nutritional Supplements Demand by Price (%), 2006

Figure 4-34: Russia - Sales Structure of New Drugs by Value & Volume (%), 2007

Figure 5-1: Russia - Population aged 65 Years & Above (in Million), 2001-2007

Figure 5-2: Russia - Commercial Drugs Demand by Price (%), 2006 & 2007

Figure 5-3: Russia - Structure of Pharmaceutical Market Growth (%), 2007

Figure 5-4: Russia - Pharmaceutical Market Growth* by Segment (%), 2007

Figure 5-5: Russia - Personal Disposable Income (in Billion US$), 2002-2007E

Figure 5-6: Russia - Share of Deaths from Cardiovascular Diseases in Total Deaths (%), 2005 & 2030F

Figure 5-7: Russia - Number of HIV Patients (in Million), 2003 & 2020F

Figure 5-8: Russia - Anti-HIV Drugs Import (in Million US$), 2004 & 2005

Figure 5-9: Russia - Forecast for Number of Diagnosed Diabetes Patients* (in '000), 2003 & 2025F

Figure 5-10: Russia - Insulin Market (in Million US$), 2006E-2008F

Figure 5-11: Russia - Share of Deaths from Cancer in Total Deaths (%), 2005 & 2030F

Figure 5-12: Russia - Generic Drugs Market (in Billion Euro), 2006 & 2010F

Figure 5-13: Russia - Number of Approved Clinical Trials (2001-2006)

Figure 5-14: Russia - Number of Patients Participating in Clinical Trials (2002 & 2006)

Figure 5-15: Russia - Clinical Trials by Therapeutic Areas (%), 2007

Figure 5-16: Russia - Clinical Trials by Sponsor Country (%), 2007

Figure 5-17: Russia - Forecast for Population (in Million), 2008-2012

Figure 6-1: Russia - Forecast for Pharmaceutical Market (in Million US$), 2008-2012

Figure 6-2: Russia - Forecast for Pharmaceutical Market by Segments (%), 2012

Figure 6-3: Russia- Forecast for Population aged 65 Years & Above (in Million) 2008-2012

Figure 6-4: Russia - Forecast for Commercial Drugs Segment (in Million US$), 2008-2012

Figure 6-5: Russia - Forecast for State Segment (in Million US$), 2008-2012

Figure 6-6: Russia - Forecast for DLO Market (in Billion US$), 2008-2012

Figure 6-7: Russia - Forecast for Personal Disposable Income (in Billion US$), 2008-2012

Figure 6-8: Russia - Forecast for Parapharmaceutical Market (in Million US$), 2008-2012

List of Tables:

Table 2-1: Global - Pharmaceutical Market by Region (in Billion US$), 2007

Table 2-2: Global - Leading Therapy Classes by Sales (in Billion US$), 2007

Table 2-3: Global - Leading Drugs by Sales (in Billion US$), 2007

Table 4-1: Russia - Leading Pharmaceutical Companies by Sales (in Million US$), 2006 & 2007

Table 4-2: Russia - Sales Structure of ATC Groups in Commercial Drugs Market, 2007

Table 4-3: Russia - Leading Pharmaceutical Companies in Commercial Drugs Market by Sales (in Million US$), 2006 & 2007

Table 4-4: Russia - Leading Drugs in Commercial Drugs Market by Sales (in Million US$), 2006 & 2007

Table 4-5: Russia - Sales Structure of ATC Groups under DLO Programme, 2007

Table 4-6: Russia - Leading Pharmaceutical Companies under DLO Programme (in Million US$), 2006 & 2007

Table 4-7: Russia - Leading Drugs under DLO Programme by Sales (in Million US$), 2006 & 2007

Table 4-8: Russia - Leading Pharmaceutical Companies under Hospital Segment (%), 2007

Table 4-9: Russia - Leading Drugs under Hospital Segment by Sales (in Million US$), 2007

Table 4-10: Russia - Leading Nutritional Supplements by Sales (in Million US$), 2005 & 2006

Table 4-11: Russia - Top 20 New Trade Names on Commercial Market (in ‘000 US$), 2007

Table 7-1: Sanofi-Aventis - Key Financials (in Million Euro), 2005-2007

Table 7-2: Novartis International AG - Key Financials (in Million US$), 2005-2007

Table 7-3: Roche Group - Key Financials (in Million CHF), 2005-2007

Table 7-4: Pfizer Inc - Key Financials (in Million US$), 2005-2007

Table 7-5: AstraZeneca Plc - Key Financials (in Million US$), 2005-2007